

# ACT Onco<sup>®</sup> + Report

PATIENT		
Identifier: 簡詔明		Patient ID: 18290410
Date of Birth: Nov 26, 1963		Gender: Male
Diagnosis: R/O cholangiocarcinoma		
ORDERING PHYSICIAN		
Name: 楊慕華醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11230878A	Collection site: Liver	Type: FFPE tissue
Date received: Jul 17, 2023	Lab ID: AA-23-04666	D/ID: NA

## ABOUT ACT Onco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
KRAS G12D	-	Cetuximab, Panitumumab

#### Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACTOnco<sup>®</sup> + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
KRAS	G12D	26.0%

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr9	CDKN2A	Homozygous deletion	0
Chr18	SMAD4	Heterozygous deletion	1

#### - Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	0.7 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 70% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 3A		
<b>KRAS G12D</b>	Cetuximab, Panitumumab	<b>resistant</b>

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

# ACT Onco<sup>®</sup> + Report

## IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

## CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

## HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

## OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### KRAS G12D

#### Biological Impact

The V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRAS) gene encodes a small GTPase protein, a member of the RAS family of small GTPases, which catalyze the hydrolysis of GTP to GDP. RAS proteins cycle between an active (GTP-bound) and an inactive (GDP-bound) state, to activate the downstream oncogenic pathways, including the PI3K/AKT/mTOR and MAPK pathways<sup>[1]</sup>. KRAS mutations occur primarily in three hotspots G12, G13 and Q61, and less frequently in codon A146<sup>[1][2]</sup>. These are activating mutations that lead to constitutive activation and persistent stimulation of the downstream signaling pathways<sup>[3][4]</sup>. Mutations in KRAS have been reported in a diverse spectrum of human malignancies, including pancreatic carcinomas (>80%)<sup>[1][5]</sup>, colon carcinomas (40-50%)<sup>[6][7]</sup>, and lung carcinomas (30-50%)<sup>[8][9]</sup>, but are also present in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia and breast cancer<sup>[2]</sup>.

G12D is a hotspot mutation located in the GTP binding region of the KRAS protein (UniProtKB). This mutation results in decreased KRAS GTPase activity, increased activation of downstream signaling, and promotes tumor formation in preclinical studies<sup>[10][11][12]</sup>.

#### Therapeutic and prognostic relevance

Cetuximab and panitumumab are FDA-approved for treating RAS wild-type metastatic colorectal cancer. The NCCN for CRC recommends that patients with any known KRAS or NRAS mutation (exons 2, 3, and 4) should not be treated with either cetuximab or panitumumab.

KRAS mutation has been determined as an inclusion criterion for the trials evaluating MEK inhibitors efficacies in various types of solid tumors (NCT03704688, NCT02399943, NCT02285439, NCT03637491, NCT04214418).

KRAS mutations are associated with a lack of efficacy of EGFR TKIs<sup>[13][14][15]</sup>. Some case reports suggest that MEK inhibitors may benefit patients with KRAS mutations, as shown in cervical and ovarian cancer cases (Am J Clin Exp Obstet Gynecol 2015;2(3):140-143)<sup>[16][17]</sup>. However, a randomized Phase II study did not find trametinib to be superior to docetaxel in KRAS-mutant non-small cell lung cancer patients<sup>[18]</sup>. MEK inhibitors as a monotherapy have limited response<sup>[19]</sup>.

Combining MEK and mTOR inhibitors is being evaluated as a potential strategy in RAS-mutant CRC<sup>[20][21]</sup>. The combination of trametinib and palbociclib has resulted in objective responses in KRAS mutant models<sup>[22]</sup>.

Sorafenib has been shown to be beneficial in KRAS-mutant CRC/NSCLC, and KRAS-amplified melanoma<sup>[23][24][25]</sup>. KRAS mutations in exon 2 (codon 12 or 13) and codon 61 have been associated with poor prognosis in CRC<sup>[26]</sup>.

Patients with KRAS or BRAF mutations in low-grade serous carcinoma of the ovary or peritoneum had better overall survival than those with wild-type genes<sup>[27]</sup>. In ovarian serous borderline tumor, KRAS G12V mutation was linked to shorter survival time<sup>[28]</sup>.

### CDKN2A Homozygous deletion

#### Biological Impact

The Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) gene encodes the p16 (p16INK4a) and p14 (ARF) proteins. p16INK4a binds to CDK4 and CDK6, inhibiting these CDKs from binding D-type cyclins and phosphorylating the retinoblastoma (RB) protein whereas p14 (ARF) blocks the oncogenic activity of MDM2 by inhibiting MDM2-induced degradation of p53<sup>[29][30][31]</sup>. CDKN2A has been reported as a haploinsufficient tumor suppressor with one copy loss that may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[32]</sup>. Loss of

# ACT Onco<sup>®</sup> + Report

CDKN2A has been frequently found in human tumors that result in uncontrolled cell proliferation<sup>[33][34]</sup>.

## Therapeutic and prognostic relevance

Intact p16-Cdk4-Rb axis is known to be associated with sensitivity to cyclin-dependent kinase inhibitors<sup>[35][36]</sup>. Several case reports also revealed that patients with CDKN2A-deleted tumors respond to the CDK4/6-specific inhibitor treatments<sup>[37][38][39]</sup>. However, there are clinical studies that demonstrated CDKN2A nuclear expression, CDKN2A/CDKN2B co-deletion, or CDKN2A inactivating mutation was not associated with clinical benefit from CDK4/6 inhibitors, such as palbociclib and ribociclib, in RB-positive patients<sup>[40][41][42]</sup>. CDKN2A loss or mutation has been determined as an inclusion criterion for the trial evaluating CDK4/6 inhibitors efficacy in different types of solid tumors (NCT02693535, NCT02187783).

The phase II TAPUR trial demonstrated clinical benefits to palbociclib monotherapy in advanced NSCLC or head and neck cancer harboring a CDKN2A mutation or copy number loss. However, pancreatic and biliary cancer patients harboring a CDKN2A mutation or copy number loss did not demonstrate an objective response or stable disease when treated with palbociclib monotherapy for 16 weeks (DOI: 10.1200/JCO.2021.39.15\_suppl.6043)<sup>[43][44]</sup>.

Notably, the addition of several CDK4/6 inhibitors to hormone therapies, including palbociclib in combination with letrozole, ribociclib plus letrozole, and abemaciclib combines with fulvestrant, have been approved by the U.S. FDA for the treatment of ER+ and HER2- breast cancer<sup>[36][45][46]</sup>.

In a Phase I trial, a KRAS wild-type squamous non-small cell lung cancer (NSCLC) patient with CDKN2A loss had a partial response when treated with CDK4/6 inhibitor abemaciclib<sup>[38]</sup>. Administration of combined palbociclib and MEK inhibitor PD-0325901 yield promising progression-free survival among patients with KRAS mutant non-small cell lung cancer (NSCLC) (AACR 2017, Abstract CT046). Moreover, MEK inhibitor in combination with CDK4/6 inhibitor demonstrates significant anti-KRAS-mutant NSCLC activity and radiosensitizing effect in preclinical models<sup>[47]</sup>.

A retrospective analysis demonstrated that concurrent deletion of CDKN2A with EGFR mutation in patients with non-small cell lung cancer (NSCLC), predicts worse overall survival after EGFR-TKI treatment<sup>[48]</sup>.

## SMAD4 Heterozygous deletion

### Biological Impact

The SMAD family member 4 (SMAD4) gene encodes a transcription factor that acts as a downstream effector in the TGF- $\beta$  signaling pathway. Upon phosphorylated and activated by serine-threonine receptor kinase, Smad4 is the Co-Smad which recruits other activated R-Smad proteins to the Smad transcriptional complex and regulate TGF- $\beta$ -targeted genes<sup>[49]</sup>. Smad4 has been identified as a haploinsufficient gene with one copy loss may lead to a weak protein expression and is insufficient to execute its original physiological function<sup>[50]</sup>. SMAD4 germline mutations are associated with juvenile polyposis syndrome (JPS)<sup>[51][52][53][54]</sup>. Somatic mutations of SMAD4 are commonly observed in pancreatic cancer<sup>[55]</sup>, colorectal cancer (CRC)<sup>[53][56][57]</sup>, and less frequently seen in other cancers such as lung adenocarcinoma<sup>[58]</sup>, head and neck cancer<sup>[59][60]</sup>, and cutaneous squamous cell carcinoma<sup>[61]</sup>.

## Therapeutic and prognostic relevance

In Chinese patients with metastatic colorectal cancer, SMAD4 or NF1 mutations are suggested as a potential biomarker for poor prognosis to cetuximab-based therapy<sup>[62]</sup>. Preclinical data demonstrated that depletion of SMAD4 by shRNA knockdown increased clonogenic survival and cetuximab resistance in HPV-negative head and neck squamous cell carcinoma cells<sup>[63]</sup>.

SMAD4 is also suggested as a predictive marker for 5-fluorouracil-based chemotherapy in colorectal cancer (CRC)<sup>[64][65]</sup>. CRC patients with normal SMAD4 diploidy exhibited three-fold higher benefit of 5-FU/mitomycin-based adjuvant therapy when compared with those with SMAD4 deletion<sup>[66]</sup>.

# ACT Onco<sup>®</sup> + Report

Results from clinical and meta-analyses showed that loss of SMAD4 in CRC, pancreatic cancer was correlated with poor prognosis<sup>[67][68][69][70][71][72][73][74]</sup>. In cervical cancer patients, weak cytoplasmic SMAD4 expression and absent nuclear SMAD4 expression were shown to be significantly associated with poor disease-free and overall 5-year survival<sup>[75]</sup>.



# ACT Onco<sup>®</sup> + Report

## US FDA-APPROVED DRUG(S)

Not Applicable.



# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
KRAS	G12D	2	c.35G>A	NM_004985	COSM521	26.0%	3951

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
BLM	I947V	15	c.2839A>G	NM_000057	-	48.9%	2319
DICER1	R617S	11	c.1851G>T	NM_177438	-	24.3%	2606
DTX1	R440C	6	c.1318C>T	NM_004416	-	51.5%	1133
ERCC5	D703G	9	c.2108A>G	NM_000123	-	49.0%	2292
FLT1	M43I	2	c.129G>A	NM_002019	-	48.4%	1600
FRG1	Splice region	-	c.62+8C>T	NM_004477	-	48.8%	1343
MUC16	Q11913P	5	c.35738A>C	NM_024690	-	47.1%	769
MUC16	I5861V	3	c.17581A>G	NM_024690	-	46.9%	1204
MUC16	K7565E	3	c.22693A>G	NM_024690	-	29.1%	1369
NBN	F603L	11	c.1809C>A	NM_002485	-	47.3%	1761
RAF1	K572T	16	c.1715A>C	NM_002880	-	47.8%	2584
ROS1	S615Y	13	c.1844C>A	NM_002944	COSM4886667	32.4%	1819
SMAD4	R100G	3	c.298A>G	NM_005359	COSM1151400	39.6%	867
USH2A	I3691L	57	c.11071A>C	NM_206933	-	50.0%	2115
ZNF217	P823L	3	c.2468C>T	NM_006526	-	52.8%	1160


### Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

# ACTOnco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Jun 29, 2023
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11230878A
- Collection site: Liver
- Examined by: Dr. Chien-Ta Chiang
- 1. The percentage of viable tumor cells in total cells in the whole slide (%): 25%
- 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 70%
- 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
- 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
- 5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 1251x
- Target Base Coverage at 100x: 95%

### RNA test

- Average unique RNA Start Sites per control GSP2: 105

# ACT Onco<sup>®</sup> + Report

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 20$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup>+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

### RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be  $\geq 10$ .

# ACT Onco<sup>®</sup> + Report

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2  $\geq 3$ ; (2) Number of supporting reads spanning the fusion junction  $\geq 5$ ; (3) Percentage of supporting reads spanning the fusion junction  $\geq 10\%$ ; (4) Fusions annotated in Quiver Gene Fusion Database.

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

醫檢師陳韻仔 博士  
Yun-Yu Chen Ph.D.  
檢字第 015647 號

Yun Yu Chen

## Sign Off

解剖病理專科醫師王業翰  
Yeh-Han Wang M.D.  
病解字第 000545 號

Yeh

# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTX	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRA5*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDMSA	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC1B1*
SLC1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------



# ACT Onco<sup>®</sup> + Report

## APPENDIX

### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
SMAD4	Cetuximab	resistant

### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS

Not Applicable.

# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 2453289; 1988, Cell;53(4):549-54  
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.
2. PMID: 2114981; 1990, Eur J Clin Invest;20(3):225-35  
ras oncogenes: their role in neoplasia.
3. PMID: 20617134; 2010, J Biomed Biotechnol;2010():150960  
Clinical relevance of KRAS in human cancers.
4. PMID: 21993244; 2011, Nat Rev Cancer;11(11):761-74  
RAS oncogenes: weaving a tumorigenic web.
5. PMID: 3047672; 1988, Nucleic Acids Res;16(16):7773-82  
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.
6. PMID: 3587348; 1987, Nature;327(6120):293-7  
Prevalence of ras gene mutations in human colorectal cancers.
7. PMID: 1942608; 1991, Nihon Shokakibyō Gakkai Zasshi;88(8):1539-44  
[Prevalence of K-ras gene mutations in human colorectal cancers].
8. PMID: 2252272; 1990, Am Rev Respir Dis;142(6 Pt 2):S27-30  
The ras oncogenes in human lung cancer.
9. PMID: 1486840; 1992, Environ Health Perspect;98():13-24  
Role of proto-oncogene activation in carcinogenesis.
10. PMID: 16474405; 2006, Nat Genet;38(3):331-6  
Germline KRAS mutations cause Noonan syndrome.
11. PMID: 26037647; 2015, Mol Cancer Res;13(9):1325-35  
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
12. PMID: 22871572; 2012, Mol Cancer Res;10(9):1228-39  
KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
13. PMID: 18349398; 2008, J Clin Oncol;26(9):1472-8  
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
14. PMID: 23401440; 2013, J Clin Oncol;31(8):1112-21  
KRAS mutation: should we test for it, and does it matter?
15. PMID: 18024870; 2007, J Clin Oncol;25(33):5240-7  
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
16. PMID: 29946554; 2018, Gynecol Oncol Rep;25():41-44  
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.
17. PMID: 26075998; 2014, Gynecol Oncol Rep;10():28-9  
Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation.
18. PMID: 25722381; 2015, Ann Oncol;26(5):894-901  
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
19. PMID: 24947927; 2014, Clin Cancer Res;20(16):4251-61

# ACT Onco<sup>®</sup> + Report

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

20. PMID: 27340376; 2016, Curr Colorectal Cancer Rep;12():141-150  
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
21. PMID: 22392911; 2012, Clin Cancer Res;18(9):2515-25  
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
22. PMID: 26369631; 2016, Clin Cancer Res;22(2):405-14  
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
23. PMID: 24407191; 2014, Br J Cancer;110(5):1148-54  
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
24. PMID: 23224737; 2013, Clin Cancer Res;19(3):743-51  
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIb or IV) non-small cell lung cancer with a KRAS mutation.
25. PMID: 26307133; 2016, Clin Cancer Res;22(2):374-82  
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
26. PMID: 15923428; 2005, Ann Oncol;16 Suppl 4():iv44-49  
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
27. PMID: 26484411; 2015, Br J Cancer;113(9):1254-8  
Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
28. PMID: 24549645; 2013, J Pathol;231(4):449-56  
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
29. PMID: 17055429; 2006, Cell;127(2):265-75  
The regulation of INK4/ARF in cancer and aging.
30. PMID: 8521522; 1995, Cell;83(6):993-1000  
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
31. PMID: 9529249; 1998, Cell;92(6):725-34  
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
32. PMID: 16115911; 2005, Clin Cancer Res;11(16):5740-7  
Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
33. PMID: 7550353; 1995, Nat Genet;11(2):210-2  
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
34. PMID: 24089445; 2013, Clin Cancer Res;19(19):5320-8  
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
35. PMID: 27849562; 2017, Gut;66(7):1286-1296  
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
36. PMID: 25524798; 2015, Lancet Oncol;16(1):25-35  
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
37. PMID: 28283584; 2017, Oncologist;22(4):416-421  
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

# ACT Onco<sup>®</sup> + Report

38. PMID: 27217383; 2016, Cancer Discov;6(7):740-53  
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
39. PMID: 26715889; 2015, Curr Oncol;22(6):e498-501  
Does CDKN2A loss predict palbociclib benefit?
40. PMID: 25501126; 2015, Clin Cancer Res;21(5):995-1001  
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
41. PMID: 27542767; 2016, Clin Cancer Res;22(23):5696-5705  
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
42. PMID: 24797823; 2014, Oncologist;19(6):616-22  
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
43. PMID: 35050752; 2020, JCO Precis Oncol;4():757-766  
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
44. PMID: 35100714; 2019, JCO Precis Oncol;3():1-8  
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
45. PMID: 27717303; 2016, N Engl J Med;375(18):1738-1748  
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
46. PMID: 28580882; 2017, J Clin Oncol;35(25):2875-2884  
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
47. PMID: 26728409; 2016, Clin Cancer Res;22(1):122-33  
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
48. PMID: 31401335; 2019, Transl Oncol;12(11):1425-1431  
Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors.
49. PMID: 25935112; 2015, Trends Biochem Sci;40(6):296-308  
Structural determinants of Smad function in TGF- $\beta$  signaling.
50. PMID: 19014666; 2008, Pathogenetics;1(1):2  
Smad4 haploinsufficiency: a matter of dosage.
51. PMID: 9545410; 1998, Am J Hum Genet;62(5):1129-36  
A gene for familial juvenile polyposis maps to chromosome 18q21.1.
52. PMID: 8553070; 1996, Science;271(5247):350-3  
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
53. PMID: 8673134; 1996, Nat Genet;13(3):343-6  
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers.
54. PMID: 18662538; 2008, Cell;134(2):215-30  
TGFbeta in Cancer.
55. PMID: 9135016; 1997, Cancer Res;57(9):1731-4  
Tumor-suppressive pathways in pancreatic carcinoma.

# ACT Onco<sup>®</sup> + Report

56. PMID: 23139211; 2013, Cancer Res;73(2):725-35  
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
57. PMID: 22810696; 2012, Nature;487(7407):330-7  
Comprehensive molecular characterization of human colon and rectal cancer.
58. PMID: 25890228; 2015, World J Surg Oncol;13():128  
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
59. PMID: 19841540; 2009, J Clin Invest;119(11):3208-11  
Smad4: gatekeeper gene in head and neck squamous cell carcinoma.
60. PMID: 15867212; 2005, Clin Cancer Res;11(9):3191-7  
Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
61. PMID: 25589618; 2015, Clin Cancer Res;21(6):1447-56  
Genomic analysis of metastatic cutaneous squamous cell carcinoma.
62. PMID: 29703253; 2018, BMC Cancer;18(1):479  
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
63. PMID: 28522603; 2017, Clin Cancer Res;23(17):5162-5175  
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
64. PMID: 16144935; 2005, Clin Cancer Res;11(17):6311-6  
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
65. PMID: 24384683; 2014, Br J Cancer;110(4):946-57  
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
66. PMID: 12237773; 2002, Br J Cancer;87(6):630-4  
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
67. PMID: 25749173; 2015, Transl Oncol;8(1):18-24  
A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.
68. PMID: 19478385; 2009, Cell Oncol;31(3):169-78  
Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.
69. PMID: 25681512; 2015, J Clin Pathol;68(5):341-5  
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
70. PMID: 26861460; 2016, Clin Cancer Res;22(12):3037-47  
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.
71. PMID: 26947875; 2016, Transl Oncol;9(1):1-7  
Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.
72. PMID: 25760429; 2015, Pancreas;44(4):660-4  
SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
73. PMID: 22504380; 2012, Pancreas;41(4):541-6  
SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
74. PMID: 19584151; 2009, Clin Cancer Res;15(14):4674-9  
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

# ACT Onco<sup>®</sup> + Report

75. PMID: 18425078; 2008, Mod Pathol;21(7):866-75  
Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.